Individual risk of type 2 diabetes (T2D) is modified by perturbations to the mass, distribution and function of adipose tissue. To investigate the mechanisms underlying these associations, we explored the molecular, cellular and whole-body effects of T2D-associated alleles near KLF14. We show that KLF14 diabetes-risk alleles act in adipose tissue to reduce KLF14 expression and modulate, in trans, the expression of 385 genes. We demonstrate, in human cellular studies, that reduced KLF14 expression increases pre-adipocyte proliferation but disrupts lipogenesis, and in mice, that adipose tissue–specific deletion of Klf14 partially recapitulates the human phenotype of insulin resistance, dyslipidemia and T2D. We show that carriers of the KLF14 T2D risk allele shift body fat from gynoid stores to abdominal stores and display a marked increase in adipocyte cell size, and that these effects on fat distribution, and the T2D association, are female specific. The metabolic risk associated with variation at this imprinted locus depends on the sex both of the subject and of the parent from whom the risk allele derives.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.

Additional information

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Change history

  • 07 August 2018

    In the version of this article originally published, minus signs were missing from the three β-values for BMI given in Table 1. The errors have been corrected in the HTML and PDF versions of the article.


  1. 1.

    Kong, A. et al. Parental origin of sequence variants associated with complex diseases. Nature 462, 868–874 (2009).

  2. 2.

    Voight, B. F. et al. Twelve type 2 diabetes susceptibility loci identified through large-scale association analysis. Nat. Genet. 42, 579–589 (2010).

  3. 3.

    Small, K. S. et al. Identification of an imprinted master trans regulator at the KLF14 locus related to multiple metabolic phenotypes. Nat. Genet. 43, 561–564 (2011).

  4. 4.

    Dang, D. T., Pevsner, J. & Yang, V. W. The biology of the mammalian Kruppel-like family of transcription factors. Int. J. Biochem. Cell Biol. 32, 1103–1121 (2000).

  5. 5.

    Wu, Z. & Wang, S. Role of kruppel-like transcription factors in adipogenesis. Dev. Biol. 373, 235–243 (2013).

  6. 6.

    Parker-Katiraee, L. et al. Identification of the imprinted KLF14 transcription factor undergoing human-specific accelerated evolution. PLoS Genet. 3, e65 (2007).

  7. 7.

    Buil, A. et al. Gene–gene and gene–environment interactions detected by transcriptome sequence analysis in twins. Nat. Genet. 47, 88–91 (2015).

  8. 8.

    Greenawalt, D. M. et al. A survey of the genetics of stomach, liver, and adipose gene expression from a morbidly obese cohort. Genome Res. 21, 1008–1016 (2011).

  9. 9.

    Civelek, M. et al. Genetic regulation of adipose gene expression and cardio-metabolic traits. Am. J. Hum. Genet. 100, 428–443 (2017).

  10. 10.

    Emilsson, V. et al. Genetics of gene expression and its effect on disease. Nature 452, 423–428 (2008).

  11. 11.

    Keildson, S. et al. Expression of phosphofructokinase in skeletal muscle is influenced by genetic variation and associated with insulin sensitivity. Diabetes 63, 1154–1165 (2014).

  12. 12.

    Innocenti, F. et al. Identification, replication, and functional fine-mapping of expression quantitative trait loci in primary human liver tissue. PLoS Genet. 7, e1002078 (2011).

  13. 13.

    van de Bunt, M. et al. Transcript expression data from human islets links regulatory signals from genome-wide association studies for type 2 diabetes and glycemic traits to their downstream effectors. PLoS Genet. 11, e1005694 (2015).

  14. 14.

    GTEx Consortium. Genetic effects on gene expression across human tissues. Nature 550, 204–213 (2017).

  15. 15.

    DIAbetes Genetics Replication And Meta-analysis (DIAGRAM) Consortium. Genome-wide trans-ancestry meta-analysis provides insight into the genetic architecture of type 2 diabetes susceptibility. Nat. Genet. 46, 234–244 (2014).

  16. 16.

    ENCODE Project Consortium. An integrated encyclopedia of DNA elements in the human genome. Nature 489, 57–74 (2012).

  17. 17.

    Roadmap Epigenomics Consortium. Integrative analysis of 111 reference human epigenomes. Nature 518, 317–330 (2015).

  18. 18.

    Fairfax, B. P. et al. Genetics of gene expression in primary immune cells identifies cell type–specific master regulators and roles of HLA alleles. Nat. Genet. 44, 502–510 (2012).

  19. 19.

    Naranbhai, V. et al. Genomic modulators of gene expression in human neutrophils. Nat. Commun. 6, 7545 (2015).

  20. 20.

    Rotival, M. et al. Integrating genome-wide genetic variations and monocyte expression data reveals trans-regulated gene modules in humans. PLoS Genet. 7, e1002367 (2011).

  21. 21.

    Hannum, G. et al. Genome-wide methylation profiles reveal quantitative views of human aging rates. Mol. Cell 49, 359–367 (2013).

  22. 22.

    Ronn, T. et al. Impact of age, BMI and HbA1c levels on the genome-wide DNA methylation and mRNA expression patterns in human adipose tissue and identification of epigenetic biomarkers in blood. Hum. Mol. Genet. 24, 3792–3813 (2015).

  23. 23.

    Najafabadi, H. S. et al. C2H2 zinc finger proteins greatly expand the human regulatory lexicon. Nat. Biotechnol. 33, 555–562 (2015).

  24. 24.

    Chen, J., Bardes, E. E., Aronow, B. J. & Jegga, A. G. ToppGene Suite for gene list enrichment analysis and candidate gene prioritization. Nucleic Acids Res. 37, W305–W311 (2009).

  25. 25.

    Garvey, W. T. et al. Pretranslational suppression of a glucose transporter protein causes insulin resistance in adipocytes from patients with non-insulin-dependent diabetes mellitus and obesity. J. Clin. Invest. 87, 1072–1081 (1991).

  26. 26.

    Horikoshi, M. et al. Discovery and fine-mapping of glycaemic and obesity-related trait loci using high-density imputation. PLoS Genet. 11, e1005230 (2015).

  27. 27.

    Global Lipids Genetics Consortium. Discovery and refinement of loci associated with lipid levels. Nat. Genet. 45, 1274–1283 (2013).

  28. 28.

    Teslovich, T. M. et al. Biological, clinical and population relevance of 95 loci for blood lipids. Nature 466, 707–713 (2010).

  29. 29.

    Locke, A. E. et al. Genetic studies of body mass index yield new insights for obesity biology. Nature 518, 197–206 (2015).

  30. 30.

    Morris, A. P. et al. Large-scale association analysis provides insights into the genetic architecture and pathophysiology of type 2 diabetes. Nat. Genet. 44, 981–990 (2012).

  31. 31.

    Shungin, D. et al. New genetic loci link adipose and insulin biology to body fat distribution. Nature 518, 187–196 (2015).

  32. 32.

    Dupuis, J. et al. New genetic loci implicated in fasting glucose homeostasis and their impact on type 2 diabetes risk. Nat. Genet. 42, 105–116 (2010).

  33. 33.

    Speliotes, E. K. et al. Genome-wide association analysis identifies variants associated with nonalcoholic fatty liver disease that have distinct effects on metabolic traits. PLoS Genet. 7, e1001324 (2011).

  34. 34.

    Chambers, J. C. et al. Genome-wide association study identifies loci influencing concentrations of liver enzymes in plasma. Nat. Genet. 43, 1131–1138 (2011).

  35. 35.

    Guo, Y. et al. Perhexiline activates KLF14 and reduces atherosclerosis by modulating ApoA-I production. J. Clin. Invest. 125, 3819–3830 (2015).

  36. 36.

    Arner, E. et al. Adipocyte turnover: relevance to human adipose tissue morphology. Diabetes 59, 105–109 (2010).

  37. 37.

    Hammarstedt, A., Graham, T. E. & Kahn, B. B. Adipose tissue dysregulation and reduced insulin sensitivity in non-obese individuals with enlarged abdominal adipose cells. Diabetol. Metab. Syndr. 4, 42 (2012).

  38. 38.

    Lonn, M., Mehlig, K., Bengtsson, C. & Lissner, L. Adipocyte size predicts incidence of type 2 diabetes in women. FASEB J. 24, 326–331 (2010).

  39. 39.

    Lundgren, M. et al. Fat cell enlargement is an independent marker of insulin resistance and ‘hyperleptinaemia’. Diabetologia 50, 625–633 (2007).

  40. 40.

    Weyer, C., Foley, J. E., Bogardus, C., Tataranni, P. A. & Pratley, R. E. Enlarged subcutaneous abdominal adipocyte size, but not obesity itself, predicts type II diabetes independent of insulin resistance. Diabetologia 43, 1498–1506 (2000).

  41. 41.

    Snijder, M. B. et al. Independent and opposite associations of waist and hip circumferences with diabetes, hypertension and dyslipidemia: the AusDiab Study. Int. J. Obes. Relat. Metab. Disord. 28, 402–409 (2004).

  42. 42.

    Yusuf, S. et al. Obesity and the risk of myocardial infarction in 27,000 participants from 52 countries: a case–control study. Lancet 366, 1640–1649 (2005).

  43. 43.

    Ernst, J. & Kellis, M. ChromHMM: automating chromatin-state discovery and characterization. Nat. Methods 9, 215–216 (2012).

  44. 44.

    Grundberg, E. et al. Mapping cis- and trans-regulatory effects across multiple tissues in twins. Nat. Genet. 44, 1084–1089 (2012).

  45. 45.

    Shabalin, A. A. Matrix eQTL: ultra fast eQTL analysis via large matrix operations. Bioinformatics 28, 1353–1358 (2012).

  46. 46.

    Storey, J. D. & Tibshirani, R. Statistical significance for genomewide studies. Proc. Natl. Acad. Sci. USA 100, 9440–9445 (2003).

  47. 47.

    Storey, J. D., Bass, A. J., Dabney, A. & Robinson, D. qvalue: Q-valueestimation for false discovery rate control. R package version 2.6.0 http://github.com/jdstorey/qvalue (2015).

  48. 48.

    Grundberg, E. et al. Global analysis of DNA methylation variation in adipose tissue from twins reveals links to disease-associated variants in distal regulatory elements. Am. J. Hum. Genet. 93, 876–890 (2013).

  49. 49.

    Tsaprouni, L. G. et al. Cigarette smoking reduces DNA methylation levels at multiple genomic loci but the effect is partially reversible upon cessation. Epigenetics 9, 1382–1396 (2014).

  50. 50.

    Pierce, B. L. et al. Mediation analysis demonstrates that trans-eQTLs are often explained by cis-mediation: a genome-wide analysis among 1,800 South Asians. PLoS Genet. 10, e1004818 (2014).

  51. 51.

    Najafabadi, H. S., Albu, M. & Hughes, T. R. Identification of C2H2-ZF binding preferences from ChIP-seq data using RCADE. Bioinformatics 31, 2879–2881 (2015).

  52. 52.

    Janky, R. et al. iRegulon: from a gene list to a gene regulatory network using large motif and track collections. PLoS Comput. Biol. 10, e1003731 (2014).

  53. 53.

    Frith, M. C., Li, M. C. & Weng, Z. Cluster-Buster: finding dense clusters of motifs in DNA sequences. Nucleic Acids Res. 31, 3666–3668 (2003).

  54. 54.

    Welter, D. et al. The NHGRI GWAS Catalog, a curated resource of SNP–trait associations. Nucleic Acids Res. 42, D1001–D1006 (2014).

  55. 55.

    Parsons, M. J. et al. The regulatory factor ZFHX3 modifies circadian function in SCN via an AT motif-driven axis. Cell 162, 607–621 (2015).

  56. 56.

    Collins, J. M., Neville, M. J., Hoppa, M. B. & Frayn, K. N. De novo lipogenesis and stearoyl-CoA desaturase are coordinately regulated in the human adipocyte and protect against palmitate-induced cell injury. J. Biol. Chem. 285, 6044–6052 (2010).

  57. 57.

    Pfaffl, M. W. A new mathematical model for relative quantification in real-time RT–PCR. Nucleic Acids Res. 29, e45 (2001).

  58. 58.

    Neville, M. J., Collins, J. M., Gloyn, A. L., McCarthy, M. I. & Karpe, F. Comprehensive human adipose tissue mRNA and microRNA endogenous control selection for quantitative real-time-PCR normalization. Obesity 19, 888–892 (2011).

  59. 59.

    Lofgren, P., Hoffstedt, J., Naslund, E., Wiren, M. & Arner, P. Prospective and controlled studies of the actions of insulin and catecholamine in fat cells of obese women following weight reduction. Diabetologia 48, 2334–2342 (2005).

  60. 60.

    Marinou, K. et al. Structural and functional properties of deep abdominal subcutaneous adipose tissue explain its association with insulin resistance and cardiovascular risk in men. Diabetes Care 37, 821–829 (2014).

  61. 61.

    Dahlman, I. et al. Numerous genes in loci associated with body fat distribution are linked to adipose function. Diabetes 65, 433–437 (2016).

  62. 62.

    Hirsch, J. & Gallian, E. Methods for the determination of adipose cell size in man and animals. J. Lipid Res. 9, 110–119 (1968).

Download references


This study was supported by MRC grant MR/J010642/1 to K.S.S., R.D.C., F.K. and M.I.M. K.S.S. is supported by an MRC New Investigator Award (MR/L01999X/1). M.I.M. is a Wellcome Senior Investigator and is supported by Wellcome (090532, 106130, 098381, 203141), NIDDK (U01-DK105535) and the MRC (MR/L020149/1). F.K. is supported by the British Heart Foundation (RG/17/1/32663). M.C. is supported by NIH Award R00 HL121172. A.L.G. is a Wellcome Senior Fellow in Basic Biomedical Science (095101/Z/10/Z and 200837/Z/16/Z). K.M. is supported by NIH award R01-DK099571, and A.J.L. is supported by NIH award NIH P01HL28481. R.D.C. is supported by MRC MC_U142661184. J.F. was a Marie Curie Fellow. M.L. is supported by Academy of Finland grants 77299 and 124243, the Finnish Heart Foundation, the Finnish Diabetes Foundation, and Commission of the European Community HEALTH-F2-2007-201681. A.V. and A.B. were supported by the European Union Framework Programme 7 grant EuroBATS (259749). Some computations were performed at the Vital-IT center for high-performance computing of the Swiss Institute of Bioinformatics (SIB; http://www.vital-it.ch/). The TwinsUK study was funded by Wellcome and European Community's Seventh Framework Programme (FP7/2007-2013). The TwinsUK study also receives support from the National Institute for Health Research (NIHR)-funded BioResource, Clinical Research Facility and Biomedical Research Centre based at Guy's and St Thomas’ NHS Foundation Trust in partnership with King's College London. We acknowledge excellent technical support for animal husbandry (Mary Lyon Centre), genotyping, histology and pathology. We thank the volunteers from the Oxford Biobank, NIHR Oxford Biomedical Research Centre, for their participation. The Oxford Biobank (http://www.oxfordbiobank.org.uk) is also part of the NIHR National Bioresource, which supported the recalling process of the volunteers. GERA data came from a grant, the Resource for Genetic Epidemiology Research in Adult Health and Aging (RC2 AG033067; C. Schaefer and N. Risch, principal investigators), awarded to the Kaiser Permanente Research Program on Genes, Environment, and Health (RPGEH) and the UCSF Institute for Human Genetics. The RPGEH was supported by grants from the Robert Wood Johnson Foundation, the Wayne and Gladys Valley Foundation, and the Ellison Medical Foundation. This research utilized data from the UK Biobank Resource under application 9161.

Author information

Author notes

  1. These authors contributed equally: Kerrin S. Small, Marijana Todorčević, Mete Civelek, Julia S. El-Sayed Moustafa and Xiao Wang.

  2. These authors jointly directed this work: Kiran Musunuru, Aldons J. Lusis, Roger D. Cox, Fredrik Karpe and Mark I. McCarthy.


  1. Department of Twin Research and Genetic Epidemiology, King’s College London, London, UK

    • Kerrin S. Small
    • , Julia S. El-Sayed Moustafa
    • , Craig A. Glastonbury
    • , Lydia Quaye
    • , Ana Viñuela
    • , Pei-Chien Tsai
    • , Abhishek Nag
    •  & Jordana T. Bell
  2. Oxford Centre for Diabetes, Endocrinology and Metabolism, University of Oxford, Churchill Hospital, Oxford, UK

    • Marijana Todorčević
    • , Momoko Horikoshi
    • , Matt J. Neville
    • , Anna L. Gloyn
    • , Fredrik Karpe
    •  & Mark I. McCarthy
  3. Center for Public Health Genomics, Department of Biomedical Engineering, University of Virginia, Charlottesville, VA, USA

    • Mete Civelek
  4. Department of Medicine, University of California, Los Angeles, Los Angeles, CA, USA

    • Mete Civelek
    • , Nam Che
    •  & Aldons J. Lusis
  5. Cardiovascular Institute, Department of Medicine, Department of Genetics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA

    • Xiao Wang
    •  & Kiran Musunuru
  6. Biocomputing, Medical Research Council Harwell Institute, Oxford, UK

    • Michelle M. Simon
    •  & Siddharth Sethi
  7. Wellcome Centre for Human Genetics, University of Oxford, Oxford, UK

    • Juan Fernandez-Tajes
    • , Anubha Mahajan
    • , Momoko Horikoshi
    • , Andrew P. Morris
    • , Anna L. Gloyn
    •  & Mark I. McCarthy
  8. Genetics of Type 2 Diabetes, Medical Research Council Harwell Institute, Oxford, UK

    • Alison Hugill
    • , Marianne Yon
    •  & Roger D. Cox
  9. Oxford NIHR Biomedical Research Centre, Churchill Hospital, Oxford, UK

    • Matt J. Neville
    • , Anna L. Gloyn
    • , Fredrik Karpe
    •  & Mark I. McCarthy
  10. Department of Human Genetics, University of California, Los Angeles, Los Angeles, CA, USA

    • Calvin Pan
    •  & Aldons J. Lusis
  11. Department of Genetic Medicine and Development, University of Geneva Medical School, Geneva, Switzerland

    • Alfonso Buil
  12. deCODE Genetics, Reykjavik, Iceland

    • Gudmar Thorleifsson
    • , Unnur Thorsteinsdottir
    •  & Kari Stefansson
  13. Harvard Medical School, Boston, MA, USA

    • Avanthi Raghavan
  14. CAS Key Laboratory of Nutrition and Metabolism, Institute for Nutritional Sciences, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, Shanghai, PR China

    • Qiurong Ding
  15. Department of Biostatistics, University of Liverpool, Liverpool, UK

    • Andrew P. Morris
  16. Faculty of Medicine, University of Iceland, Reykjavik, Iceland

    • Unnur Thorsteinsdottir
    •  & Kari Stefansson
  17. Institute of Clinical Medicine, Internal Medicine, University of Eastern Finland and Kuopio University Hospital, Kuopio, Finland

    • Markku Laakso
  18. Department of Medicine, Huddinge, Karolinska Institutet, Stockholm, Sweden

    • Ingrid Dahlman
    •  & Peter Arner
  19. Department of Microbiology, Immunology and Molecular Genetics, University of California, Los Angeles, Los Angeles, CA, USA

    • Aldons J. Lusis


  1. Search for Kerrin S. Small in:

  2. Search for Marijana Todorčević in:

  3. Search for Mete Civelek in:

  4. Search for Julia S. El-Sayed Moustafa in:

  5. Search for Xiao Wang in:

  6. Search for Michelle M. Simon in:

  7. Search for Juan Fernandez-Tajes in:

  8. Search for Anubha Mahajan in:

  9. Search for Momoko Horikoshi in:

  10. Search for Alison Hugill in:

  11. Search for Craig A. Glastonbury in:

  12. Search for Lydia Quaye in:

  13. Search for Matt J. Neville in:

  14. Search for Siddharth Sethi in:

  15. Search for Marianne Yon in:

  16. Search for Calvin Pan in:

  17. Search for Nam Che in:

  18. Search for Ana Viñuela in:

  19. Search for Pei-Chien Tsai in:

  20. Search for Abhishek Nag in:

  21. Search for Alfonso Buil in:

  22. Search for Gudmar Thorleifsson in:

  23. Search for Avanthi Raghavan in:

  24. Search for Qiurong Ding in:

  25. Search for Andrew P. Morris in:

  26. Search for Jordana T. Bell in:

  27. Search for Unnur Thorsteinsdottir in:

  28. Search for Kari Stefansson in:

  29. Search for Markku Laakso in:

  30. Search for Ingrid Dahlman in:

  31. Search for Peter Arner in:

  32. Search for Anna L. Gloyn in:

  33. Search for Kiran Musunuru in:

  34. Search for Aldons J. Lusis in:

  35. Search for Roger D. Cox in:

  36. Search for Fredrik Karpe in:

  37. Search for Mark I. McCarthy in:


K.S.S., A.L.G., K.M., A.J.L., R.C., F.K. and M.I.M. conceived of and designed the project; M.T., M.C., J.S.E.-S.M., M.M.S., J.F.-T., C.A.G., L.Q., C.P., P.-C.T., A.N. and G.T. analyzed data; M.T., X.W., A.H., S.S., M.Y., N.C., A.R. and Q.D. performed experiments; A.M., M.H., M.J.N. and A.V. contributed experimental and technical support as well as discussions; A.B., A.P.M., J.T.B., U.T., K.S., M.L., I.D. and P.A. contributed data; K.S.S., M.T., M.C., J.S.E.-S.M., M.M.S., K.M., A.J.L., R.C., F.K. and M.I.M. wrote the manuscript; and all authors read and approved of the manuscript.

Competing interests

M.I.M. has received consulting and advisory board honoraria from Pfizer, Lilly and NovoNordisk; and G.T., U.T. and K.S. are employees of deCODE Genetics/Amgen.

Corresponding authors

Correspondence to Kerrin S. Small or Mark I. McCarthy.

Integrated supplementary information

  1. Supplementary Figure 1 Sex-stratified and parent of origin effects on the KLF14 trans- eQTL.

    QQ-plots of association between rs473102 and all adipose probes in the deCODE dataset (female N=376 and male N=265). Top row displays results from standard genotypic tests, bottom row displays results for test of association to maternally inherited allele

  2. Supplementary Figure 2 Geographic distribution of rs4731702 in the Human Genome Diversity Panel.

    The ancestral T2D risk allele C is colored in orange, the derived allele T in blue. Figure generated from the HGDP Selection Browser at the Pritchard Lab (http://hgdp.uchicago.edu/cgi-bin/gbrowse/HGDP/). rs4731702 does not display evidence of positive selection in the HGDP – with global FST in the 80th percentile genome-wide and non-significant iHS and XP-EHH scores in all populations71. Tests for recent positive selection at rs4731702 in samples from the United Kingdom using the Singleton Density Score (SDS) were not significant (P=0.20), but the trend was towards a recent increase of the non-risk allele T72. By contrast, the KLF14 transcript does exhibit evidence of intolerance to variation in the ExAC exome aggregation dataset73 (ExAC constraint scores: Missense z= 2.32; Synonymous z = 2.41) suggesting coding changes in KLF14 are under purifying selection

  3. Supplementary Figure 3 Distinct 450K methylation probes at the KLF14 locus are associated to rs4731702 vs age.

    Figure shows results for two 450K probes assayed in the TwinsUK adipose samples (N=603). cg02385110, which is ~3KB upstream of KLF14 is shown on the left, cg08097417 which is at the KLF14 transcription start site is shown on the right. The beta distributions (top row), association to rs4731702 (T2D risk allele homozygotes = 2) (middle row) and association to age (bottom row) differ between the two probes. cg02385110 has a higher mean beta value, is associated to rs4731702 (P=2.1x10-7), and is not associated to age (P=0.64). In contrast, cg08097417 is not associated to rs4731702 (P=0.99) but is highly associated to age (P=3.6x10-61). Associations were tested with linear mixed effect models adjusting for batch effects, BMI and famlly structure

  4. Supplementary Figure 4 Clinical chemistry analysis of heterozygous Klf14tm1(KOMP)Vlcg knockout mice.

    Clinical chemistry parameters were measured in male knockout C57BL/6N Klf14 mice and their wildtype controls. Since Klf14 is mono-allelically maternally expressed in mouse and human, we compared heterozygous mice that had inherited the deletion allele from their mother (heterozygous-MAT, expressing the deletion) with heterozygous mice that had inherited the deletion allele from their father (heterozygous-PAT, not expressing the deletion). We also compared the two groups to their own homozygous wildtype colonymate controls (wildtype-MAT and wildtype-PAT). This was because we used two separate crosses to produce the MAT and PAT carrier cohorts; one stock from heterozygous mothers and one from heterozygous fathers, each crossed to wildytpe C57BL/6N mice. Mice were fed a standard diet and then switched at 18-weeks of age to a 45kcal% high fat diet. Comparing across the timecourses for (a), HDL-C; (b), insulin; (c), glucose; (d), IPGTT by calculating area under the curve, base-lined to t=0 values (data not shown), and analysing with a 1-way ANOVA non-parametric Kruskal-Wallis test and Dunns multiple comparison test we found: that HDL-C (a) was lower in MAT compared to either PAT or wildtype-MAT (p= 0.0055 and 0.0086 respectively) and that wildtype-PAT compared to PAT was not significantly (p=0.56) different; that insulin (b) was lower in MAT compared to either PAT or wildtype-MAT (p= <0.0003 and 0.0020 respectively) and that wildtype-PAT compared to PAT was not significantly (p>0.99) different; that Glucose (c) was lower in MAT compared to PAT (p= <0.0001) and that wildtype–MAT and wildtype-PAT compared to MAT and PAT respectively were not significantly (p=0.79 and >0.99 respectively) different; and that for an IPGTT (d) none of the group comparisons were significantly different (p>0.99) to each other. Then to examine effects at specific times for (a) HDL-C, (b) insulin, (c) glucose and (d) IPGTT individual pairwise comparisons were made at each timepoint using a Mann-Whitney 2-tailed t-test and were significantly reduced in the MAT group compared to PAT group at 8, 22 and 27 weeks in (a,b,c) and at all timepoints in (d). The MAT groups were also significantly lower compared to wildtype-MAT for HDL-C and insulin at 22 and 27 weeks. Values are expressed as mean ± SD and in (a,b,c) wildtype-MAT n=16, wildtype-PAT n=9, heterozygous-MAT n=15, heterozygous-PAT n=16 and in (d) wildtype-MAT n =19, wildtype-PAT n=10, MAT n=16, PAT n=16. For (e), HDL-C; (f), LDL-C and (g), total cholesterol was measured in a 33-week blood sample collected under terminal anaesthetic and was significantly, using an unpaired 2-tailed t-test, reduced in heterozygous-MAT mice compared to PAT mice. Values are expressed as mean ± SD (PAT N =8, MAT N =8). Wildtype MAT grey, wildtype PAT black, MAT KO red, PAT KO blue lines and fill

  5. Supplementary Figure 5 Clinical chemistry and histological analyses of global CRISPR-Cas9 KO mice.

    Clinical chemistry parameters were measured in female and male CRISPR-Cas9 knockout (KO) C57BL/6J Klf14 mice and their wildtype (Wt) controls. Mice were fed a standard diet throughout their lifetimes. (a), HDL-C at 12 weeks of age was significantly reduced in female and reduced with borderline significance in male (unpaired two-tailed t-test). (b), triglycerides at 12 weeks of age were not significantly different in females or males (unpaired two-tailed t-test). Comparing across the IPGTT timecourses (c and d) by calculating area under the curve, base-lined to t=0 values, (data not shown) and analysing using a Mann-Whitney two-tailed t-test showed there was no significant difference between male or female KO and wildtype mice (p=0.23 and 0.93 respectively). Then in order to make comparisons at each timepoint for (c and d), individual pairwise Mann-Whitney 2-tailed t-tests were carried out, and as for AUC no differences were found in the female data, although in males glucose levels were nominally higher at 20, 60 and 120 minutes of the test. (e and f), ITT at 16 weeks was not significantly changed between wildtype and KO groups of either female (e) or male (f) mice, analysed by 2-way ANOVA with repeated measures and Bonferroni correction. Values are expressed as mean ± SD and in (a,b) female wildtype n=9, female KO n=9, male Wt n=9, male KO n=9 and in (c,d,ef) female wildtype n=9, female KO n=8, male Wt n=9, male KO N=9. Wildtype mice in blue lines and fill, KO mice in red lines and fill

  6. Supplementary Figure 6 Gluteal adipose tissue of T2D risk allele homozygotes contains fewer, larger mature adipocytes compared to non-risk allele homozygotes.

    Adipocyte cell area in histological sections of subcutaneous gluteal adipose biopsies from the Oxford BioBank. a, Median cell area in female (N=18, mean ± SEM) and male (N=18, mean ± SEM) gluteal biopsies stratified by genotype at rs4731702. b, Cumulative frequency distribution of adipocyte cell area in females (N=18). c, Cumulative frequency distribution of adipocyte cell area in males (N=18). Statistical significance was assessed using a Wilcoxon signed-rank two-sided test

Supplementary information

  1. Supplementary Text and Figures

    Supplementary Figures 1–6, Supplementary Note and Supplementary Tables

  2. Life Sciences Reporting Summary

  3. Supplementary Tables

    Supplementary Tables 1, 5, 6, 8 and 9

About this article

Publication history






Further reading